2. Search Result
Search Result
Results for "

Irinotecan hydrochloride

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

3

Natural
Products

5

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16562A
    Irinotecan hydrochloride
    Maximum Cited Publications
    45 Publications Verification

    (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan hydrochloride
  • HY-16568
    Irinotecan hydrochloride trihydrate
    Maximum Cited Publications
    45 Publications Verification

    (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate
  • HY-16562S1
    Irinotecan-d10 hydrochloride

    		Isotope-Labeled Compounds Topoisomerase Autophagy Cancer
    Irinotecan-d10 (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1][2].
    Irinotecan-d10 hydrochloride
  • HY-16562
    Irinotecan
    Maximum Cited Publications
    45 Publications Verification

    (+)-Irinotecan; CPT-11; VAL-413(free base)

    		 Topoisomerase Autophagy Cancer
    Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan
  • HY-100620
    RPR121056

    APC

    		 Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE .
    RPR121056
  • HY-16568R
    Irinotecan hydrochloride trihydrate (Standard)

    		Topoisomerase Autophagy Cancer
    Irinotecan (hydrochloride trihydrate) (Standard) is the analytical standard of Irinotecan (hydrochloride trihydrate). This product is intended for research and analytical applications. Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate (Standard)
  • HY-16562R
    Irinotecan (Standard)

    		Topoisomerase Autophagy Cancer
    Irinotecan (Standard) is the analytical standard of Irinotecan. This product is intended for research and analytical applications. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan (Standard)
  • HY-146269
    11-Desethyl Irinotecan

    		Others Cancer
    11-Desethyl Irinotecan is a camptothecin (CPT) analog and one of the metabolites of irinotecan. It is promising for cancer research .
    11-Desethyl Irinotecan
  • HY-16562S
    Irinotecan-d10

    (+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10

    		 Topoisomerase Autophagy Cancer
    Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
    Irinotecan-d10
  • HY-16562AS
    Irinotecan-d5 hydrochloride

    (+)-Irinotecan-d5 hydrochloride; CPT-11-d5 hydrochloride; VAL-413-d5

    		 Autophagy Topoisomerase Isotope-Labeled Compounds Cancer
    Irinotecan-d5 hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan-d5 hydrochloride
  • HY-141436
    Sucrosofate potassium

    Sucrose octasulfate potassium

    		 Biochemical Assay Reagents Cancer
    Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .
    Sucrosofate potassium
  • HY-126373
    SN-38 glucuronide

    SN-38G

    		 Drug Metabolite Cancer
    SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide
  • HY-126373S1
    SN-38 glucuronide-13C6

    SN-38G-13C6

    		 Isotope-Labeled Compounds Others
    SN-38 glucuronide- 13C6 is the 13C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide-13C6
  • HY-145513
    CL2-MMT-SN38

    		Topoisomerase Cancer
    CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .
    CL2-MMT-SN38
  • HY-164271
    10-Boc-SN-38

    		Topoisomerase Cancer
    10-Boc-SN-38 is a tert-butyloxycarbonyl (Boc)-protected form of SN-38 (HY-13704). SN-38 is the active metabolite of Irinotecan (HY-16562) .
    10-Boc-SN-38
  • HY-153013
    SN38-COOH

    		Drug-Linker Conjugates for ADC Cancer
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis .
    SN38-COOH
  • HY-168516
    FXR/CES2 modulator 1

    		FXR Others
    FXR/CES2 modulator 1 (compound LE-77) is a doul modulator that activates FXR and inhibits CES2. FXR/CES2 modulator 1 effectively mitigates the intestinal toxicity of irinotecan .
    FXR/CES2 modulator 1
  • HY-147388
    hiCE inhibitor-1

    		Others Metabolic Disease
    hiCE inhibitor-1, a sulfonamide derivative, is a selective human intestinal enzyme (hiCE) inhibitor with a Ki value of 53.3 nM. hiCE inhibitor-1 can be used to improve Irinotecan (HY-16562)-induced diarrhoea .
    hiCE inhibitor-1
  • HY-14871
    Tenifatecan

    SN2310

    		 Topoisomerase Cancer
    Tenifatecan (SN2310) is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan). Tenifatecan (SN2310) possesses anticancer activity .
    Tenifatecan
  • HY-155034
    Antitumor agent-102

    		Topoisomerase GLUT Cancer
    Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .
    Antitumor agent-102
  • HY-155228
    LK-44

    		Others Inflammation/Immunology
    hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .
    LK-44
  • HY-13704
    SN-38
    40+ Cited Publications

    7-Ethyl-10-hydroxycamptothecin

    		 Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38
  • HY-139909
    CL2E-SN38

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38
  • HY-139909A
    CL2E-SN38 TFA

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38 TFA
  • HY-136170
    MC-SN38

    		Drug-Linker Conjugates for ADC Cancer
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks .
    MC-SN38
  • HY-13704S
    SN-38-d3

    NK012-d3

    		 Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].
    SN-38-d3
  • HY-155181
    hCES2-IN-1

    		Others Cancer
    hCES2-IN-1 (Compound 24) is a reversible and selective hCES2 inhibitor (IC50: 6.72 μM). hCES2-IN-1 reduces the level of hCES2 in living cells. hCES2-IN-1 is effective against Irinotecan (HY-16562)-induced delayed diarrhea and DSS-induced ulcerative colitis .
    hCES2-IN-1
  • HY-13704R
    SN-38 (Standard)

    		Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38 (Standard)
  • HY-12757
    YHO-13177
    2 Publications Verification

    		 BCRP Cancer
    YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .
    YHO-13177
  • HY-146080
    Antitumor agent-61

    		Apoptosis Cancer
    Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .
    Antitumor agent-61

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: